NAD+

Overview

What is NAD+ and why it is not a peptide

This is an important opening point, because NAD+ is often mentioned in the context of “research peptides”, but chemically it belongs to an entirely different category. NAD+ is not a peptide — it is a dinucleotide coenzyme, more similar to ATP and other nucleotides than to amino-acid chains.

The NAD+ molecule consists of:

• Nicotinamide (a derivative of vitamin B3, niacin)
• Adenine (a purine base, the same as in DNA/RNA/ATP)
• Two riboses (sugars)
• A pyrophosphate bridge (two phosphate residues linked together)

Chemically, then, NAD+ belongs to the family of dinucleotides together with NADH (the reduced form), NADP+ and NADPH. In the Molequa portfolio it appears as a non-peptide research molecule, similarly to MK-677 — a layer that complements peptide molecules in certain research contexts (especially for longevity).

Central role in cellular metabolism

NAD+ is the most important coenzyme in the cell. That is not an exaggeration — without NAD+ hundreds of enzymatic reactions would stop and the cell would die within minutes. Three main roles:

1. Redox cofactor in energy metabolism. NAD+ and its reduced form NADH participate in all major metabolic pathways — glycolysis, the Krebs cycle, fatty-acid oxidation. In every oxidative reaction of the cell, NAD+ is converted to NADH, which then delivers electrons in the mitochondrion to produce ATP. Without NAD+ there is no ATP. Without ATP there is no life.

2. Substrate for sirtuins (SIRT1 to SIRT7). Sirtuins are a family of enzymes that deacetylate proteins — removing acetyl groups from lysines on histones (which regulates gene expression) and on other proteins (which regulates metabolism and stress response). Sirtuins are the key “longevity enzymes” — their activation in animal models extends lifespan. Sirtuins ABSOLUTELY need NAD+ as a substrate; without NAD+ they do not function.

3. Substrate for PARPs (poly-ADP-ribose polymerases). PARPs are DNA-repair enzymes. At every DNA damage event (UV, free radicals, replication errors) PARPs “scan” the DNA and initiate repair processes. They consume enormous amounts of NAD+ in the process. In more severe damage, PARPs can completely deplete the cellular NAD+ pool and the cell dies (paradoxically, from lack of energy).

Age-related decline in NAD+ — the aging hypothesis

This is one of the best-documented hypotheses in the aging field. NAD+ levels decline with age:

• 40-year-old adults have ~50 % of the NAD+ levels of 20-year-olds
• 60-year-old adults have ~25 % of younger NAD+ levels
• The decline is visible in all tissues — muscle, liver, brain, skin, blood

The mechanism of decline is multifactorial:

1. Increased CD38 activity — the enzyme that breaks NAD+ down. CD38 expression rises with age due to chronic inflammation.
2. PARP hyperactivation — chronic DNA damage with age (oxidative stress, telomere dysfunction) depletes NAD+ via PARPs.
3. Drop in NAD+ synthesis — reduced activity of the enzymes NAMPT, NMNAT with age.
4. Drop in precursor availability — nicotinamide, NMN, NR.

Result: a “NAD+ crisis” in aging cells. Sirtuins do not function properly, DNA repairs are impaired, mitochondrial function declines. This is the molecular framework for many aspects of biological aging.

Hypothesis: replenish NAD+, slow aging

From this comes an attractive therapeutic hypothesis: if we replenish NAD+, we can reverse or slow some aspects of aging. This is the central idea of the research by David Sinclair (Harvard), Shin-ichiro Imai (Washington University) and other “NAD+ apostles” in the longevity field.

In animal models it works. Older mice receive NAD+ (or the precursor NMN or NR) and:

• Mitochondrial function improves
• Muscle strength and endurance are restored
• Cognition improves
• Lifespan is extended
• Fertility capacity is restored in old mice

In humans the data are more cautious. Phase 2 trials with NMN and NR (oral NAD+ precursors) have shown biochemical effects (increase in plasma NAD+) but mixed clinical endpoints. Phase 3 data are still missing.

Direct NAD+ administration vs precursors (NMN, NR)

This is a frequent question in research. Three main options:

Direct NAD+ is preferable when you want a rapid elevation of the intracellular NAD+ pool. NMN and NR are preferable for long-term maintenance thanks to oral bioavailability.

In the research context, NAD+ is often administered as an IV infusion (250 to 1000 mg) at clinics offering “NAD+ therapy”. This use is off-label and has not been formally validated, but a growing body of research suggests it can be effective for some indications.

Mechanism of action — multiple pathways

Energy metabolism

NAD+ is a cofactor in glycolysis, the Krebs cycle and β-oxidation. At higher NAD+ levels:

• Higher rate of ATP production
• Better mitochondrial function
• Increased fatty-acid oxidation
• Better metabolic flexibility

Sirtuin activation

Sirtuins (SIRT1 to 7) are activated at higher NAD+ levels. The most important effects:

• SIRT1: deacetylation of FOXO transcription factors → stress resistance; deacetylation of PGC-1α → mitochondrial biogenesis
• SIRT3 (mitochondrial): deacetylation of mitochondrial enzymes → better OXPHOS efficiency
• SIRT6: stabilization of telomeres, DNA repairs
• SIRT2: regulation of metabolism and the cell cycle

Sirtuin activation is the main longevity mechanism associated with NAD+.

Optimization of DNA repair

PARPs with a sufficient NAD+ pool effectively repair DNA damage. With NAD+ deficiency DNA damage accumulates and leads to genomic instability — one of the main hallmarks of aging.

Anti-inflammatory effects via CD38 inhibition

Higher NAD+ levels can inhibit CD38 through feedback and thereby reduce chronic inflammation (“inflammaging”). This is a secondary mechanism, but clinically relevant.

Neurological effects

NAD+ is critical for neuronal function. The brain has high energy demand and sirtuins in neurons (especially SIRT1, SIRT3) regulate neuroprotection, plasticity, and cognition. In Alzheimer’s, Parkinson’s and other neurodegenerative diseases a local NAD+ deficit is observed in the affected neurons.

Investigated applications

In the published preclinical and clinical literature, the effects of NAD+ (and its precursors) are documented in the following areas:

• Age-related decline of functions — robustly demonstrated in animal models
• Mitochondrial dysfunctions — emerging clinical data
• Neurodegenerative diseases (Alzheimer’s, Parkinson’s) — Phase 2 trials
• Chronic fatigue syndrome — observational data, IV NAD+ therapy
• Addiction treatment — alcohol, opioids (anecdotal, some studies)
• Metabolic syndrome and insulin resistance — Phase 2 data with NMN
• Cardiovascular function — endothelial function, blood pressure
• Skin aging — cosmetic research
• Post-COVID long-term symptoms — emerging research
• Sarcopenia — preclinical and Phase 2 data

Science & studies

4.1 Key publications

Imai S., Guarente L. (2014). NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24(8):464 to 471. Foundational review article.

Mills K.F., Yoshida S., Stein L.R., et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 24(6):795 to 806. Key animal study.

Yoshino M., Yoshino J., Kayser B.D., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 372(6547):1224 to 1229. First randomized clinical trial of NMN.

Martens C.R., Denman B.A., Mazzo M.R., et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 9(1):1286. Clinical validation of NR.

Trammell S.A., Schmidt M.S., Weidemann B.J., et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 7:12948. Pharmacokinetic study.

Verdin E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science. 350(6265):1208 to 1213. Review article.

4.2 Detailed expandable studies

▸ Study 1: Imai & Guarente 2014 — foundational review article

Citation: Imai S., Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464 to 471.

What they did: Review article by two founders of the NAD+/sirtuin field. Imai and Guarente were key in discovering the sirtuin deacetylase activity in the 1990s. They cover: NAD+ biochemistry, sirtuin biology, age-related changes, therapeutic perspectives.

What they found (summary):

• NAD+ levels decline linearly with age in all tissues
• Sirtuins are “glucose sensors” — activated during caloric restriction and fasting
• The decline in NAD+ leads to “pseudohypoxia” in aging cells
• Supplementation with NAD+ precursors in animal models restores sirtuin activity
• Therapeutic perspectives: NMN, NR, sirtuin activators, CD38 inhibitors

Why it matters: This is the reference article for the entire field. For the research context it provides the conceptual framework in which NAD+ exists as a longevity molecule. The Imai-Guarente hypothesis is today the best-developed molecular theory of aging.

▸ Study 2: Mills 2016 — key animal study

Citation: Mills K.F., Yoshida S., Stein L.R., et al. Long-Term Administration of NMN Mitigates Age-Associated Physiological Decline in Mice. Cell Metab. 2016;24(6):795 to 806.

What they did: Long-term study. Aging C57BL/6N mice (from 5 months to ~16 months) received NMN in drinking water at doses of 100 or 300 mg/kg/day. Duration: 12 months (the longest NMN study to that date). Assessment: body weight, body composition, insulin sensitivity, lipid profile, physical activity, bone density, ophthalmologic parameters, cognition.

What they found:

• Prevention of age-related changes in gene expression — NMN-treated mice had an expression profile closer to young mice
• Restoration of mitochondrial function in multiple tissues
• Improvement of insulin sensitivity of 35 to 50 %
• Preserved muscle strength and endurance
• Preserved bone density
• Better vision (NMN-treated mice had a slower decline in ophthalmologic parameters)
• No serious adverse effects

Why it matters: This is the most ambitious preclinical study of NMN/NAD+ in animal aging models. It demonstrated that long-term supplementation with NAD+ precursors can slow many aspects of aging in mice. It became the basis for the human clinical trials that followed. For the research context it is robust proof of concept.

▸ Study 3: Yoshino 2021 — first RCT of NMN in humans

Citation: Yoshino M., Yoshino J., Kayser B.D., et al. NMN increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224 to 1229.

What they did: n = 25 postmenopausal women with prediabetes and obesity. Randomized double-blind placebo-controlled study. NMN 250 mg orally daily vs placebo. Duration: 10 weeks. Primary endpoint: change in insulin signaling in muscle (via muscle biopsy).

What they found:

• Significant improvement in muscle insulin signaling (AKT/mTOR pathway)
• Increased expression of genes for mitochondrial biogenesis
• Increased expression of tissue remodeling
• Drop in HOMA-IR of ~25 %
• No adverse events

Why it matters: This was the first high-quality randomized clinical trial of NMN in humans. Publication in Science gave the NAD+ field academic legitimacy. Limitations: small sample, one type of patients (postmenopausal women with prediabetes), short duration. But a proof of concept for the human translation of NAD+ research.

▸ Study 4: Martens 2018 — chronic NR supplementation

Citation: Martens C.R., Denman B.A., Mazzo M.R., et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018;9(1):1286.

What they did: n = 30 healthy middle-aged and older adults (55 to 79 years). Randomization: NR 500 mg orally 2× daily (1 g/day total) vs placebo. Duration: 6 weeks per phase, cross-over design. Assessment: plasma NAD+ pool, blood pressure, arterial stiffness, glycemia, lipid profile.

What they found:

• Plasma NAD+ increased by 60 % in the NR arm
• Mild reduction of systolic blood pressure by 6 mmHg
• Improvement in arterial stiffness (markers of endothelial function)
• No effect on glycemia in the healthy population
• Excellent safety profile — no serious adverse events

Why it matters: The study validated the oral bioavailability of NR and the ability to long-term increase the NAD+ pool in humans. From a safety perspective it is an important publication — NR became a safe supplement with real biochemical effects. NMN has a more complicated regulatory status in the US (the FDA excluded it from the dietary category in 2022); NR remains available as Niagen.

▸ Study 5: Trammell 2016 — pharmacokinetics

Citation: Trammell S.A., Schmidt M.S., Weidemann B.J., et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:12948.

What they did: Pharmacokinetic study of NR after oral administration in mice and humans (n = 12 healthy volunteers). Monitoring of plasma levels of NR, NMN, NAD+, NADH, nicotinamide, nicotinic acid at various time points (5 min, 30 min, 1 h, 2 h, 4 h, 8 h, 24 h).

What they found:

• NR is rapidly absorbed orally — peak at 30 minutes
• NR is converted to NAD+ in multiple tissues — liver, muscle, blood
• Plasma NAD+ rises 2 to 8× after a single dose
• Optimal dosing regimens: 100 to 1000 mg
• No accumulation of toxic metabolites

Why it matters: This is the reference pharmacokinetic publication for NR and NMN. It demonstrates that NAD+ precursors really do reach intracellular targets. For the research context it provides a quantitative framework for dosing protocols. Limitation: direct measurement of intracellular NAD+ in different tissues in humans is technically challenging; most data are from plasma or peripheral cells (PBMCs).

▸ Study 6: Verdin 2015 — review article in Science

Citation: Verdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208 to 1213.

What they did: Review article in Science. Eric Verdin (Buck Institute) summarized the state of the NAD+ field: biochemistry, mitochondrial function, sirtuins, PARP, CD38, neurological applications, therapeutic perspectives.

What they found (summary):

• NAD+ is “the integrator of metabolic and stress signals”
• The decline in NAD+ with age is a causal factor, not merely a correlation
• PARP and CD38 are the main consumers of NAD+ in aging cells
• Selective CD38 inhibitors are a new therapeutic option
• NAD+ has potential in neurodegeneration (Alzheimer’s, Parkinson’s, ALS)

Why it matters: Verdin’s review in Science gave the NAD+ field academic prestige. For the research context it expanded the perspective from pure longevity to specific clinical indications — especially neurodegenerative diseases, where mitochondrial dysfunction and NAD+ deficit play a central role.

▸ Study 7: Grant 2019 — IV NAD+ clinical observational study

Citation: Grant R., Berg J., Mestayer R., et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Front Aging Neurosci. 2019;11:257.

What they did: Pilot study of a human IV NAD+ infusion. n = 8 healthy volunteers received 750 mg NAD+ as a 6-hour IV infusion. Assessment: changes in the plasma and urinary NAD+ metabolome via LC-MS, clinical symptoms, vital signs.

What they found:

• Plasma NAD+ did not rise directly — it was rapidly metabolized
• Plasma nicotinamide and methyl-nicotinamide rose markedly — markers of NAD+ metabolism
• NAD+ likely reaches tissues as its metabolites (not as whole NAD+)
• Clinically, patients subjectively reported increased energy during and after the infusion
• No serious adverse events during the 6-hour IV infusion

Why it matters: The study provides rare clinical data on IV NAD+ — the administration route used by “NAD+ clinics” off-label. Conclusion: direct IV NAD+ has a real biological effect, although the mechanism is more complex than simple replenishment of the NAD+ pool (via metabolites). For the research context this validates IV NAD+ as a legitimate entry route for experimental use.

Storage

Lyophilizate (dry powder before reconstitution)

• 3 years at −20 °C (freezer)
• 2 years at 2 to 8 °C (refrigerator)
• Only short-term (up to 7 days) at room temperature — NAD+ is less stable than peptides
• Protect from light and moisture (extremely hygroscopic)

After reconstitution (NAD+ in solution)

• Only 7 to 14 days at 2 to 8 °C — NAD+ has a shorter shelf life in solution than peptides
• A NAD+ solution is especially sensitive to light, heat, and pH changes
• For long-term storage after reconstitution: freeze in aliquots at −20 °C, use within 3 months

Practical storage rules

• Let the vial warm to room temperature (15 to 20 min) before opening. NAD+ is hygroscopic (attracts moisture from the air); condensation can rapidly degrade the lyophilizate.
• Darkness is your friend — NAD+ is sensitive to UV light. The adenine component of the molecule absorbs at 260 nm.
• Avoid contact with reducing agents — cysteine, glutathione, ascorbate, DTT. Reduction of NAD+ → NADH changes the pharmacological profile.
• pH control is important — NAD+ is stable at neutral pH (6.5 to 7.5). Acidic pH (< 5) accelerates hydrolysis to nicotinamide and ADP-ribose.
• Do not shake! Even though NAD+ is not a peptide, mechanical stress can contribute to degradation.
• The solution should remain colorless or very slightly yellow. A brownish color indicates degradation — do not use.

Reconstitution

3-step visual

1. Reconstitute — add bacteriostatic water down the wall of the vial
2. Measure — use the calculator (Section 8) to compute the required volume
3. Store — refrigerator 2 to 8 °C, protect from light

Detailed protocol

What you will need:

• NAD+ vial (250 mg lyophilizate)
• 5 to 10 mL bacteriostatic water (NAD+ requires a higher solvent volume than peptides due to larger doses)
• Insulin syringe 1 mL or a regular 5 to 10 mL syringe

Procedure:

1. Let the NAD+ vial reach room temperature (15 to 20 min). A cold vial + warm water = condensation that disrupts NAD+ stability.
2. Disinfect the rubber stoppers of both vials (NAD+ + BAC water) with a disinfecting swab (70 % isopropyl alcohol). Let the alcohol evaporate.
3. Draw the required volume of BAC water with the syringe. The standard for a 250 mg vial is 5 mL → resulting concentration 50 mg/mL = 50 000 µg/mL.
4. Inject the water slowly down the wall of the vial. Never directly onto the lyophilizate. NAD+ dissolves faster than peptides, but still with care.
5. Let the vial rest for 2 to 3 minutes. NAD+ is well soluble in water, but at higher concentrations dissolution can be slower.
6. Gently swirl the vial in circular motions (NEVER shake!) for 60 seconds until all the powder dissolves. The solution should be completely clear to very slightly yellow.
7. Store in the refrigerator at 2 to 8 °C, in a dark box. Protection from light is critical for NAD+.

Alternative volumes for different final concentrations

Rule of thumb: For NAD+ we recommend 5 mL volume for a 250 mg vial (50 mg/mL). At this concentration, a typical 100 mg dose = 2 mL per injection, which is volumetrically manageable for subcutaneous administration.

For IV administration: Clinical “NAD+ clinics” typically dilute NAD+ in 250 to 500 mL of saline and administer it as a slow infusion (3 to 6 hours at a 250 to 1000 mg dose). This is not recommended for amateur research use — IV administration requires sterile conditions and clinical supervision.

Stacking tips — Frequently combined peptides and molecules

In the research literature NAD+ is often part of longevity combination protocols — addressing the mitochondrial and sirtuin axis that is complementary to other longevity mechanisms.

MOTS-c — parallel mitochondrial support

The most logical combination partner for NAD+. MOTS-c activates the AMPK pathway and stimulates mitochondrial biogenesis. NAD+ provides substrate for sirtuins and coenzymatic support for the Krebs cycle and OXPHOS. Together they cover two independent axes of mitochondrial function — energetics and regulatory signaling.

Epithalon — complementary longevity axis

Epithalon addresses cellular aging via telomeres and gene expression. NAD+ addresses metabolic aging via sirtuins and mitochondria. Two independent hallmarks of aging — a strong theoretical basis for combination.

Resveratrol or Pterostilbene — sirtuin activators

These are non-peptide small molecules with direct activator capacity on SIRT1. When combined with NAD+, a “dual sirtuin stimulation” arises — more substrate (NAD+) + direct activator (resveratrol). A classic longevity combination described by David Sinclair.

Spermidine — autophagy

Spermidine induces autophagy (the cellular recycling process). NAD+ supports sirtuins, which regulate the autophagy program. A complementary mechanism. In Sinclair’s protocols they are combined.

Metformin — AMPK activator

Metformin activates AMPK (same as MOTS-c). NAD+ supports sirtuins. AMPK and sirtuins have overlapping targets, the combination can be supra-additive. But: metformin can paradoxically inhibit mitochondrial function in complex I, the relationship with NAD+ is complex and requires careful research design.

Semaglutide or Tirzepatide — metabolic complement

GLP-1 agonists address appetite and weight. NAD+ addresses mitochondrial function in remaining muscle mass. With rapid weight reduction by GLP-1 agonists, muscle NAD+ also drops; replenishment may be relevant.

BPC-157 and TB-500 — regeneration

In training or in regeneration after injuries, tissue energy demand rises. NAD+ supports the energetics of regenerating cells; BPC-157/TB-500 stimulate regeneration pathways. A complementary combination for research in sports medicine.

FAQ — Frequently asked questions

Is NAD+ a peptide? No. NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme/nucleotide — a molecule composed of nicotinamide, adenine, two riboses, and a pyrophosphate bridge. Functionally it is more similar to ATP than to peptides. In the Molequa portfolio it appears as a non-peptide research molecule (similarly to MK-677), included as a functional complement to peptide molecules for longevity (Epithalon, MOTS-c).

What is the difference between NAD+, NMN and NR? All three are ways to raise the intracellular NAD+ pool:

Molequa offers direct NAD+ — preferable when you want a rapid increase in the intracellular pool. For long-term oral supplementation, NMN or NR are more practical.

Does NAD+ work orally? Very limited. Orally administered NAD+ breaks down in the stomach and small intestine into nicotinamide and ADP-ribose. Only a fraction survives to the blood. For effective replenishment of the NAD+ pool either:

• Injectable administration of NAD+ (SC or IV)
• Oral precursors (NMN, NR), which are better absorbed

are preferable.

What is the plasma half-life of NAD+? Only ~5 minutes — NAD+ is rapidly metabolized in the blood by CD38 and other enzymes into nicotinamide and metabolites. But the intracellular NAD+ pool can be maintained elevated for hours to days after administration, because:

1. Tissues have their own NAD+ recycling pathways
2. Metabolites (nicotinamide) are reused for synthesis of NAD+ inside cells
3. A NAD+ dose “kicks off” the whole system even when the molecule itself disappears quickly

What is the recommended dosing in research protocols? From the published literature and clinical practice of NAD+ clinics:

Subcutaneous (SC):

• 50 to 250 mg daily or every other day
• Cyclically: 5 days on, 2 days off

Intravenous (IV):

• 250 to 1000 mg as a slow infusion (3 to 6 hours)
• Clinical “NAD+ therapy” protocols: typically 500 to 750 mg 1 to 3× weekly

For NMN/NR (orally):

• 250 to 1000 mg daily

Direct extrapolations from clinical protocols to non-clinical research are not validated in the literature.

Are adverse effects known? NAD+ has a predominantly favorable safety profile:

Common (>10 % with IV infusion):

• Chest pressure and tightness during infusion, typically with fast IV (resolves on slowing)
• Mild nausea
• Headaches during and after the infusion
• Mild blood-pressure rise during the infusion

Less common (1 to 10 %):

• Local reaction at the SC injection site
• Mild fatigue as a compensatory response
• Mild sweating

Rare but important:

• With fast IV there can be an unpleasant sensation in the chest and whole body (“wave of discomfort”), so a slow infusion (3 to 6 hours) is recommended
• CD38 enzyme hyperactivity can paradoxically rapidly break down the administered NAD+

Who should NOT take NAD+ (in the research context)? Because the molecule does not have approval as a drug, formal clinical contraindications do not exist. Research protocols typically exclude:

• Pregnancy and lactation
• Severe cardiovascular diseases (arrhythmias)
• Active oncological diseases (NAD+ supports cell growth, including potentially tumor cells — preventive caution)
• Schizophrenia and other psychotic states (anecdotal — NAD+ can affect serotonin and dopamine)
• Severe mitochondrial diseases (effects unpredictable)

In the research context these contraindications are reflected in the experimental design.

Will NAD+ extend my life? In animal models there is evidence — NMN supplementation in mice extended some aspects of healthspan, but the absolute lifespan extension was mild (Mills 2016: +6 % in females, not in males). In humans the evidence does not exist — follow-up takes decades.

Honest framing: NAD+ is one of the most promising candidates for longevity, but clinical validation of human longevity is in its infancy. The strongest data are for healthspan (healthy aging), not for maximum lifespan.

Does NAD+ cause cancer? A theoretical concern exists, but the data do not confirm it. NAD+ supports cellular energetics, including cancer cells. But it also activates sirtuins and PARPs in parallel, which have anti-oncogenic functions (DNA repairs, genome regulation). In the published human and animal data no increased tumor incidence has been recorded.

In the research context it is recommended to avoid NAD+ in persons with an active history of oncological disease.

What is the WADA status? NAD+ is not explicitly on the WADA Prohibited List 2026. As an endogenous molecule with a metabolic role it is theoretically covered by category S0 (Non-Approved Substances), but direct bans do not exist. For professional athletes, consultation with the anti-doping authority before use is recommended, especially for IV administration.

Can NAD+ be combined with peptides? In the research context, yes — NAD+ and peptides have different mechanisms and no proven interactions. Combinations:

• NAD+ + MOTS-c — mitochondrial synergy
• NAD+ + Epithalon — complementary longevity pathways
• NAD+ + BPC-157/TB-500 — energy support of regeneration
• NAD+ + Ipamorelin/CJC-1295 — anabolic pathways

Clinical data for these combinations are still missing, but the theoretical foundations are strong.

Why does NAD+ have such varying price levels in the market? Three factors:

1. Purity — research-grade NAD+ is more expensive than technical
2. Form — disodium hydrate (most stable) vs free acid
3. Package size — IV clinics use large vials (1 g+), which lowers the per-mg price

Molequa offers research-grade NAD+ with HPLC ≥99 % purity in sizes optimized for research protocols.

What is the purity of this batch? The current batch 2026-04-O: ≥ 99.2 % HPLC. The full CoA with HPLC chromatogram, MS spectrum (confirmation MW 663.43 Da) and related-impurity profile is available for download or upon request. For NAD+ we specifically check the level of reduction to NADH (< 2 %) — a critical parameter, because NADH has different pharmacology.